Loading
Immune side-effects are usually treated with high-dose steroids, which may also switch off the anti-cancer response. Targeted alternatives may control the side-effect and keep the benefit.
High cumulative corticosteroid exposure for immune-related adverse events is associated with worse cancer outcomes in several cohorts, although confounding by severity is hard to exclude. Targeted alternatives (early infliximab or vedolizumab for colitis, tocilizumab for arthritis and some pneumonitis, topical or organ-directed therapy) could resolve toxicity with less systemic immunosuppression. A randomised comparison has never been done with cancer outcome as an endpoint.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Immune-related adverse events (irAEs), No one can predict who responds to immunotherapy, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Immune-related adverse events (irAEs), No one can predict who responds to immunotherapy, Toxicity and quality of life are undervalued, Immune checkpoint inhibitors.
Shares Immune-related adverse events (irAEs), Renal cell carcinoma, Toxicity and quality of life are undervalued, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Monoclonal antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.